Physician profile
Melissa Denniston
NPI 1083449995
$1,427.09
in general payments reported to CMS, 2019-2025
13 companies · $1,427 in 2025
The $1,427 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,427.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $384.45 | 2025 | |
| Janssen Pharmaceuticals, INC | $188.71 | 2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $182.07 | 2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Axsome Therapeutics, INC. | $149.43 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $125.00 | 2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $118.04 | 2025 | Austedo Xr |
| Alkermes, INC. | $95.72 | 2025 | Aristada, Vivitrol, Aristada Initio |
| Indivior INC. | $49.89 | 2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $45.69 | 2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $36.32 | 2025 | Abilify Asimtufii |
| Lilly USA, LLC | $20.04 | 2025 | Zepbound |
| Echosens North America, INC. | $16.63 | 2025 | Fibroscan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.10 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Denniston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.